Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-55308942 in Bipolar Depression
2021-004790-31Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing JNJ-55308942 with Placebo (2 arms). Primary endpoint: Change in MADRS total score from baseline at Week 6. Started Mar 2022; status: active.
02
Drugs
zanvipixant
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2021-004790-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004790-31.